Eli Lilly participated in a series B round for the cardiorenal treatment specialist that will support clinical drug trials, boosting its overall funding to $193m.
US-based cardiorenal treatment developer CinCor Pharma received $143m on Tuesday in a series B round that included Lilly Asia Ventures, a venture capital firm sponsored by pharmaceutical firm Eli Lilly. Growth equity firm General Atlantic Led the round, which included Perceptive Advisors, BVF Partners, VenBio Partners, Omega Funds, RTW Investments, Adage Capital Management, Rock Springs…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.